Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 445 across all filing types
Latest filing 2025-12-09 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物信息披露管理制度（2025年12月修订）
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled "Information Disclosure Management System" for a company, outlining procedures, responsibilities, and regulatory compliance related to information disclosure. It references various laws and regulations governing disclosure, the roles of board members and management, and the types of reports and announcements the company must make. It does not contain financial statements, audit results, earnings data, or any specific event announcements. Instead, it is a governance and compliance manual related to disclosure practices. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-12-09 Chinese
益方生物股东会议事规则（H股上市后适用）
Governance Information Classification · 95% confidence The document is titled as "益方生物科技（上海）股份有限公司 股东会议事规则（草案）（H 股发行并上市后适用）" which translates to "Rules of Procedure for Shareholders' Meetings (Draft) (Applicable after H-share issuance and listing)". The content extensively details the rules, procedures, and regulations governing shareholders' meetings, including the rights and duties of shareholders, meeting convocations, voting procedures, and resolutions. It references relevant laws and listing rules but does not contain financial statements, earnings data, or audit information. It is a governance-related document outlining internal rules and procedures for shareholder meetings rather than a report of financial results or announcements of voting outcomes. Therefore, it fits best under Governance Information (CGR). The document length is substantial and contains detailed governance rules, not a brief announcement or a report publication notice.
2025-12-09 Chinese
益方生物董事会议事规则（H股上市后适用）
Governance Information Classification · 100% confidence The document is titled "益方生物科技（上海）股份有限公司 董事会议事规则（草案）" which translates to "Rules of Procedure for the Board of Directors" of the company. The content extensively details the structure, duties, responsibilities, meeting procedures, and governance related to the Board of Directors. It references relevant laws and listing rules, and outlines the internal governance framework for the board. There is no financial data, audit information, or report publication mentioned. The document is clearly a governance-related document focusing on board rules and procedures. Therefore, it fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance rules, not just an announcement or summary, so it is not a Regulatory Filing or Report Publication Announcement. Hence, the classification is CGR with high confidence.
2025-12-09 Chinese
益方生物股东通讯政策（H股上市后适用）
Governance Information Classification · 95% confidence The document is titled as a "Shareholder Communication Policy" (股东通讯政策) for a company after its H-share issuance and listing. It outlines principles and methods for communication between the company and its shareholders, including references to regulatory requirements from the Hong Kong Stock Exchange (HKEX) listing rules. The content focuses on governance practices related to shareholder communication, the responsibilities of the board, and procedural details for shareholder meetings and inquiries. There are no financial statements, audit information, earnings data, or other report content. The document is a governance-related policy document rather than a financial report or announcement. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 1604 characters, which is short but contains substantive policy content, not just an announcement or notice, so it is not RPA or RNS.
2025-12-09 Chinese
益方生物董事会提名委员会议事规则（H股上市后适用）
Governance Information Classification · 100% confidence The document is titled "提名委员会议事规则 (草案)" which translates to "Nomination Committee Meeting Rules (Draft)" for a company after its H-share listing. It details the structure, responsibilities, procedures, and governance of the Nomination Committee of the Board of Directors. The content focuses on governance practices, committee composition, duties, meeting procedures, and related rules. There is no financial data, no mention of financial results, no voting results, no announcements of reports, no legal proceedings, no capital changes, or other categories. The document is a governance-related internal rules document, specifically about the nomination committee's operation and governance. Therefore, the most appropriate classification is Governance Information (CGR). The document length is over 5,000 characters and contains detailed governance rules, not a brief announcement or a report publication notice.
2025-12-09 Chinese
益方生物关于聘请H股发行及上市的审计机构的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the appointment of an audit firm for the company's H-share issuance and listing. It details the selection process, qualifications of the audit firm, and the need for shareholder approval. The document does not contain any financial statements or audit reports themselves, but rather announces the intention to hire an auditor for a future listing. The document length is short (1309 characters), and it is clearly an announcement rather than a full audit report or annual report. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2025-12-09 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.